Oncogenes and Chromosomal Aberrations The Story of Abl and the Philadelphia Chromosome.

Slides:



Advertisements
Similar presentations
Molecular Aspects of Lymphocyte Transformation and Neoplasia
Advertisements

Imatinib Resistance Geoffrey L. Uy, M.D. Associate Professor of Medicine Division of Oncology.
The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
Acute Myelogenous Leukemia and its Impact on the Immune System
1 Leukemia. 2 Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of A group of malignant disorders affecting the blood.
I’ve just been diagnosed with CML. Could you answer my questions?
LEUKEMIA.
Armaan Khalid. What is Leukaemia?  Cancer of the blood or bone marrow  Can be classified: Acute/chronic Myeloid/lymphoid.
Chronic leukaemias Chronic myelogenous leukaemia Chronic myelogenous leukaemia Chronic lymphocytic leukaemia Chronic lymphocytic leukaemia.
LEUKEMIA—HEMATOLOGY {S1}
ApoptosisNecrosis Apoptosis is a form of programmed cell death Apoptosis is responsible for the formation of digits in the developing mouse paw. Apoptotic.
E2A and acute lymphoblastic leukemias (ALL). A closer look at the E2A gene... Other names: TCF3, ITF1, and Factors E12/E47 Located on chromosome 19 Encodes.
Leukemia is characterized by hyperproliferation of immature white blood cells white blood cell Leukemic patientnormal person red blood cells hyperproliferation.
Notch1 and pre-T-cell Acute Lymphoblastic Leukemia (T-ALL) by Lindsey Wilfley.
PDGF β Receptor. Protein 1106 amino acid protein Weinberg Fig 5.10.
Copyright (c) by W. H. Freeman and Company Chapter 24 Cancer.
Molecular Medicine. Focus on Cancer Most chemotherapies were developed before the human genome was sequenced Many are alkylating agents that attach methyl.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Anticancer Therapy: Kinase Inhibitors Charles Harrell.
Rakesh Biswas MD Professor, Medicine, People's College of Medical Sciences, Bhopal, India Lecture first conceived and delivered to medicine undergrads.
Chapter 17 Chronic Leukemias.
Chronic leukemias. Chronic myelogenous (granulocytic) leukemia Is characterized by an unregulated proliferation of myeloid elements in the bone marrow,
Chronic myeloid leukaemia. THE STORY OF CHRONIC MYELOID LEUKAEMIA ‘It is moreover, the same conclusion which Bennett came to in the much-discussed matter.
Marty O’Neill II Carmen Banea
Chronic Myeloid Leukemia Leukemia ALL, AML, CLL ALL, AML, CLL Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia –Cancer of the granulocytes or.
CHRONIC MYELOID LEUKAEMIA Dr Rosline Hassan Department of Haematology School of Medical Sciences Universiti Sains Malaysia.
Fusion Genes in Cancer Wednesday, June 27th. Outline: Transcription Fusion genes Examples of fusion genes in cancer Summary and conclusions.
Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.
Molecular Medicine Dr Catherine Flynn Consultant Haematologist St James’s Hospital October 22 nd 2009.

Leukemia is characterized by hyperproliferation of immature white blood cells white blood cell Leukemic patientnormal person red blood cells hyperproliferation.
C HRONIC LEUKEMIAS. Chronic myelogenous (granulocytic) leukemia Is characterized by an unregulated proliferation of myeloid elements in the bone marrow,
Acute Leukemia and the FLT3 Receptor B y: Betty Sa’ Mentor: Dr. Govind Bhagat Site: Columbia University Vanderbilt Clinic.
Chapter 4 Cellular Oncogenes ~ Mar 22, 2007.
Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.
Genetic Mutations that Lead to Chronic Myelogenous Leukemia: Causes and Treatments Marty O’Neill II & Carmen Banea
Here are some CML slides that may be helpful for your presentation.
Finding Cancer Genes.
Interesting Developments. Historic trends in biotech fields.
Case Study MICR Hematology Spring, 2011 Case # 5 Hee Jin Kim, Hooman Nikizad and Arthur Omuro.
hyperproliferation of white blood cells
Leukemia By: Gabie Gomez. What is Leukemia? Blood consists of plasma and three types of cells, each type has a special function. RBC, WBC and Platelets.
Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.
Heterogeneous group of hematopoietic neoplasms Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation Composed.
What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of.
White blood cells and their disorders Dr K Hampton Haematologist Royal Hallamshire Hospital.
Chronic Myeloid Leukemia
The Biology of Cancer Second Edition CHAPTER 4 Cellular Oncogenes
Chronic Myelocytic Leukemia Mark D. Browning, M.D. Oncology/Hematology Associates February 26, 2016.
Malignancies of hematopoietic cells. Leukemia
LEUKEMIAS H.A. MWAKYOMA, MD.
CLINICAL PROGRESSION INTRODUCTION METHOD CONCLUSION REFERENCES
hyperproliferation of white blood cells
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Peyton Rous discovered a virus that causes cancer in chickens
hyperproliferation of white blood cells
E2A: master regulator of B-cell lymphopoiesis
HS 4160 Critical Scientific Analysis
17 Chapter 17: Chromosome 17 Nucleus 48,473 bp 882 aa RARA Cytoplasm
Case Study ….
Chapter 17: Regulation of cell number
CASE STUDY Leukemia.
hyperproliferation of white blood cells
(T-cell Acute Lymphoblastic Leukemia)
Neoplastic disorder.
Chronic Leukemia Dr. Noha Noufal.
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
Attacking Cancer at Its Root
Presentation transcript:

Oncogenes and Chromosomal Aberrations The Story of Abl and the Philadelphia Chromosome

Wikipedia The Hematopoietic System myeloidlymphoid self renewal granulocytes

Leukemia – malignancy of the white blood cells and their precursors. myelogenous leukemias lymphocytic leukemias self renewal

Molecular Cell Biology Lodish et al. Fig Leukemia is characterized by hyper- proliferation of immature white blood cells Acute (fast, children and adults) Chronic (slow, adults)

Figure 8.32 The Biology of Cancer (© Garland Science 2007) Chronic Myelogenous Leukemia (CML) elevated numbers of differentiated neutrophils less differentiated blast cells are “taking over” the blood is full of blast cells

basophil blast neutrophils and precursors promyelocyte

Molecular Cell Biology Lodish et al. Fig CML arises in a stem cell that is a granulocyte precursor.

Chronic Myelogenous Leukemia (CML) Annual incidence: 1/100,000 people (~15% of all leukemias) Median age: yrs Median survival: 4 yrs with conventional chemotherapy 6 yrs with aIFN therapy; Allogeneic (human) bone marrow transplantation may cure the patient.

CML - Pathology Chronic Phase – Accumulation of myeloid cells bone marrow peripheral blood spleen and liver elsewhere Accelerated Phase – Further genetic changes in the stem cell leading eventually to acute transformation (i.e. acute leukemia) and death

“The findings suggest a causal relationship between the chromosome abnormality observed and chronic granulocytic leukemia.” Peter Nowell 1960 Nowell and Hungerford find that one copy of chromosome 22 is extremely short in CML patients

The tiny Philadelphia chromosome is a clear and consistent marker of CML. Nowell and Hungerford, University of Pennsylvania, Philadelphia

Janet Rowley in 1998 Upon receiving the Lasker Award What caused this chromosome aberration?

A chromosomal translocation triggers CML healthy individualleukemic patient Chr. 9 Chr. 22 9; 22 Translocation The Philadelphia chromosome

Karyotype courtesy of L. J. Beauregard, Eastern Maine Medical Center A characteristic karyotype indicates CML

Acute Lymphoblastic Leukemia (ALL) Affects precursor of leukocytes (B and T cells) Ph+ chromosomes in 20% of adult ALL 2-5% of childhood ALL In adults prognosis is very poor (Only % of adults with ALL survive 2 years) Bone marrow transplant the only long term treatment Figure 2.8a The Biology of Cancer (© Garland Science 2007) tumors exhibiting a pre-B lymphocyte marker

The v-abl containing retrovirus was recovered from a tumor found in mice infected by Moloney Leukemia virus Abelson and Rabstein, Cancer Res 30, 2213 (1970) The Abelson viral oncogene

v-abl is cloned Rosenberg and Witte,

The v-abl sequence is used as a probe to find homologous cellular sequences. Next step: using v-abl and c-abl as probes to map c-abl to a chrmosome. How? Mouse-human somatic hybrids.

mouse cell linehuman cells

abl is mapped to chromosome 9 healthy individual leukemic patient Chr. 9 Chr. 22 abl 9; 22 Translocation De Klein et al. Nature 300, 765 (1982) abl and is translocated to the Philadelphia chromosome in CML patients near the translocation site of CML patients. Does abl translocate in CML patients? mouse cells Human CML cells

The Philadelphia chromosome translocation fuses the bcr and abl genes Chr. 9 Chr. 22 abl bcr bcr-abl 9; 22 Translocation fuses bcr and abl Groffen et al. Cell 36, 93 (1984) healthy individual leukemic patient bcr= (breakpoint cluster region)

Figure 4.15a The Biology of Cancer (© Garland Science 2007) The translocation results in production of a fusion protein that joins the amino-terminal end of the Bcr protein to most of the Abl protein

Figure 4.15b The Biology of Cancer (© Garland Science 2007) The translocation results in production of a fusion protein that joins the amino-terminal end of the Bcr protein to most of the Abl protein

Daley et al. Science (1990) Bcr-Abl is sufficient to cause leukemia !!

Fluorescence In Situ Hybridization (FISH) a tool for diagnosing CML ablbcr

fusion 9 abl/bcr fusion 22 bcr/abl abl bcr Fluorescence In Situ Hybridization (FISH) a tool for diagnosing CML BCRABL The current methd: PCR.

Nagar JN(2007) Abelson kinase A fatty-acid modified and actin-binding non-receptor tyrosine kinase So, what makes Bcr-Abl sufficient to cause leukemia?

Src is normally inactive due to intramolecular inhibition.

c-Abl SH3 FG SH2 kinase Actin- binding FG Gag v-Abl FG Bcr Bcr-Abl myristate How does Bcr-Abl cause cancer?

Nagar et al. Cell 112:859 (2003) The structure of Abl reveals a novel mode of intramolecular inhibition the N-terminal myristate binds to a pocket on the kinase domain

Harrison Cell 112, 737 (2003) Src and Abl Distinct yet analogous modes of regulation

A multistep mechanism for activating Src Harrison Cell 112, 737 (2003)

A proposed mechanism for activating Abl Harrison Cell 112, 737 (2003)

c-Abl SH3 FG SH2 kinase Actin- binding FG Gag v-abl FG Bcr Bcr-Abl myristate Abl w/o a myr residue is oncogenic

But what does Abl normally do?

Insights From the Mouse Model abl mutant mice are viable but have a shortened lifespan. They also have problems with: male fertility B cell maturation osteoblasts and bone formation Truncation of C-terminus leaving an intact kinase has same phenotype as the null mutant

Abelson Has a Twin Brother SH3 FG SH2kinase Actin- binding FG 89%94%27%34% Abl Arg

Are Abl and Arg redundant? arg mutant mice have behavioral defects (Arg is expressed in the brain at high levels) abl; arg double mutants have defects in neural tube and are embryonic lethal Wild-type abl; arg

modified from Weisberg et al. Nature Reviews Cancer 7 (2007) Constitutively active Abl promotes proliferation and survival even in the absence of growth factors. Abl at the Cellular Level

Focal adhesion proteins are phosphorylated by Abl.

Rac is required for Bcr-Abl–dependent proliferation and invasiveness. Skorski et al. PNAS, 95 (1998) 24h black: cells expressing Bcr-Abl white: cells expressing Bcr-Abl and a DN Rac mutant adhesion motility Calbiochem

Bcr-Abl Cytoskeleton/ adhesion defects S G 2 M 1 G G0G0 Apoptosis Stem cell turnover Proliferation & differentiation Bcr-Abl affects multiple cell functions. Adapted from Jörgensen, Hem. Onc.

Why are increased motility and survival and reduced adhesion relevant for leukemias? Gabrilovich Nature Reviews Immunology 4 (2004)

Imatinib (Gleevec) or, why should we do basic studies? In chronic phase 30% of patients have no detectable sign of disease, 50% in remission Also has some effect on patients in blast crisis for whom other treatments are not effective Plus—relatively few serious side-effects

STI571 Gleevec blocks the ATP binding site of the kinase domain

Table 4.5 The Biology of Cancer (© Garland Science 2007)